Guardant Health (GH) is trading lower on April 30, 2026 as the market digests FDA briefing materials released ahead of the Oncologic Drugs Advisory Committee (ODAC) discussion of AstraZeneca’s camizestrant. The central issue for GH is that SERENA-6 relies on Guardant’s Guardant360 CDx liquid biopsy to identify emergent ESR1 mutations in circulating tumor DNA and guide an early switch in endocrine therapy, tying part of Guardant’s perceived growth optionality to the regulatory outcome and the FDA’s view of the trial design and endpoints. (tipranks.com)

Even though Guardant is not the drug sponsor, the FDA’s skepticism around whether the “switch at ESR1-mutation detection before radiographic progression” strategy demonstrates clinically meaningful benefit can translate into lower expectations for how quickly (or how broadly) Guardant360 CDx could expand in this specific monitoring-style use case. The FDA agenda for April 30 explicitly frames camizestrant’s proposed use around ESR1-mutation emergence during first-line endocrine-based therapy “based on an FDA approved test,” which keeps attention on the companion-diagnostic workflow and how it would be implemented in real-world practice. (fda.gov)

Key near-term swing factors include the tone of the ODAC discussion and any signals about whether the evidence package is adequate for the proposed indication and diagnostic-triggered treatment strategy. For GH, traders will also watch for read-through to demand expectations for Guardant360 CDx in breast cancer monitoring scenarios and whether investor focus rotates back toward Guardant’s own operating trajectory and upcoming quarterly results timeline. (tipranks.com)